Compare VRAX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | EVAX |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United Kingdom | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 42.7M |
| IPO Year | 2022 | 2021 |
| Metric | VRAX | EVAX |
|---|---|---|
| Price | $0.41 | $5.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $12.33 |
| AVG Volume (30 Days) | ★ 570.8K | 116.5K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,986.00 | ★ $7,650,000.00 |
| Revenue This Year | $217,274.83 | $128.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 132.17 |
| 52 Week Low | $0.31 | $1.20 |
| 52 Week High | $3.20 | $12.15 |
| Indicator | VRAX | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 49.47 | 50.53 |
| Support Level | $0.33 | $4.56 |
| Resistance Level | $0.44 | $5.02 |
| Average True Range (ATR) | 0.04 | 0.43 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 50.33 | 47.22 |
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.